Allergan: beats consensus in Q4
(CercleFinance.com) - Allergan announces Q4 2019 adjusted EPS that is up 21.
7% at 5.22 dollar, thereby beating the consensus by about sixty cents the consensus, while its revenues rose by 6.6 % to 4.35 billion dollars.
The pharmaceutical laboratory - based in Ireland - therefore reported FY 2019 adjusted EPS that is up 5.7% at 17.64 dollars, for revenues that are up 1.9% to almost 16.1 billion dollars.
In addition, Allergan says that it expects to complete its current deal with AbbVie towards the end of Q1 2020, subject to receiving the required regulatory approvals, along with the satisfaction of other conditions.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
7% at 5.22 dollar, thereby beating the consensus by about sixty cents the consensus, while its revenues rose by 6.6 % to 4.35 billion dollars.
The pharmaceutical laboratory - based in Ireland - therefore reported FY 2019 adjusted EPS that is up 5.7% at 17.64 dollars, for revenues that are up 1.9% to almost 16.1 billion dollars.
In addition, Allergan says that it expects to complete its current deal with AbbVie towards the end of Q1 2020, subject to receiving the required regulatory approvals, along with the satisfaction of other conditions.
Copyright (c) 2020 CercleFinance.com. All rights reserved.